The AMS Group of companies specialise in the design, development, manufacture and distribution of novel, high performance tissue-healing technologies, including advanced wound care products, surgical dressings and medical grade materials as well as medical adhesives and sutures for closing and sealing tissue.

AMS Group plc was founded in 1991 in Winsford, Cheshire, U.K.  It was originally set up to offer R&D, manufacturing and Sales & Marketing capabilities providing advanced wound care products for major healthcare companies.  In 2002 the Group acquired Advanced Medical Solutions (Plymouth) Limited (formerly MedLogic Global Ltd) based in Plymouth, Devon. This provided the Group with technology in cyanoacrylate based medical adhesives and a direct U.K. sales force.  Advanced Medical Solutions (Plymouth) Limited and Advanced Medical Solutions Limited completed an entity merger in June 2018 and both now operate under Advanced Medical Solutions Limited.

In October 2009, following a successful joint venture with Recticel, the Group acquired the Netherlands based hydrophilic polyurethane manufacturer Corpura B.V. (now known as Advanced Medical Solutions B.V.).

In 2011 the Group further expanded acquiring RESORBA Wundversorgung GmbH & Co KG (now known as RESORBA Medical GmbH), a long established wound care and wound closure business, providing suture and collagen technologies, headquartered in Germany with direct sales in Germany, the Czech Republic and Russia.

In January 2019, the Group acquired Sealantis Limited, a developer of an alginate-based tissue adhesive technology platform. Sealantis is an Israeli-based medical device company with a patent-protected alga-mimetic sealants technology platform with a wide range of potential surgical indications under development. Its two most advanced surgical sealant products are Seal-G, an open surgery device already CE marked for reinforcement of the staple / suture line to minimise anastomotic leaks following gastrointestinal surgery, and Seal-G MIST (Minimally Invasive Spray Technology) the equivalent laparoscopic device for the same indication but performed through key hole surgery.

In December 2019, the Group acquired Biomatlante SA, a well-established international developer and manufacturer of innovative surgical biomaterial technologies. Biomatlante is a French-based medical device company with a patent-protected technology platform with a wide range of biomaterial products used in orthopaedic, spinal, dental and sports surgery and a development pipeline of next-generation products. Biomatlante’s commercialised products, which are approved for sale in over 50 countries worldwide, include synthetic bone substitutes, collagen membranes and bioabsorbable screws. The acquisition will strengthen AMS’s product portfolio, R&D pipeline, and market access. Biomatlante is ISO 13485 and MDSAP accredited with extensive clinical evidence and is well prepared for the new European Medical Device Regulation.

In November 2020, the Group acquired Raleigh Adhesive Coatings Limited, an independent woundcare and bio-diagnostics coatings business. Raleigh is a UK based company which brings in-house specialist services of acrylic and silicone coating, perforation processing and some bulk materials converting capabilities which are currently outsourced. Silicone coating and perforation capabilities are particularly important to AMS as they are intrinsic to all modern advanced woundcare foam dressings. Raleigh is an existing key supplier, producing the coated adhesive mesh used in the new LiquiBand® XL device, an important part of the Group’s continued US growth strategy and currently undergoing clinical trials. In addition, Raleigh’s expertise will allow the Company to enter the bio-diagnostic testing sector.

AMS is listed on the Alternative Investment Market (AIM).

Today the Group has a global customer base, operates out of 10 locations and employs over 700 people

The AMS Group operates through two Divisions each responsible for their respective sales, marketing and Research and Development (R&D) activities. Both Divisions focus on a different strategic route to market.

Our products and materials are sold in over 75 countries worldwide, and we have over 100 distribution partners.

Our Locations